-
Mashup Score: 6Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD - 1 day(s) ago
On December 16, the FDA approved tapinarof (Vtama) cream 1% for individuals with atopic dermatitis aged 2 years and older. The approval followed the conclusi…
Source: www.youtube.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 1FDA Approves Tapinarof 1% Cream for Adult, Pediatric Patients with Atopic Dermatitis - 10 day(s) ago
The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
🚨 BREAKING 🚨 #Tapinarof (Vtama) cream 1% was approved by the FDA as a treatment for adult/pediatric patients with #AtopicDermatitis aged 2 years+ The announcement took place ahead of tapinarof’s extended PDUFA date of March 12, 2025. View the news 👇 https://t.co/Vb8ed0M5PB
-
-
Mashup Score: 1FDA Approves Tapinarof 1% Cream for Adult, Pediatric Patients with Atopic Dermatitis - 11 day(s) ago
The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
🚨 BREAKING 🚨 #Tapinarof (Vtama) cream 1% was approved by the FDA as a treatment for adult/pediatric patients with #AtopicDermatitis aged 2 years+ The announcement took place ahead of tapinarof’s extended PDUFA date of March 12, 2025. View the news 👇 https://t.co/Vb8ed0M5PB
-
-
Mashup Score: 1FDA Approves Tapinarof 1% Cream for Adult, Pediatric Patients with Atopic Dermatitis - 11 day(s) ago
The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
🚨 BREAKING 🚨 #Tapinarof (Vtama) cream 1% was approved by the FDA as a treatment for adult/pediatric patients with #AtopicDermatitis aged 2 years+ The announcement took place ahead of tapinarof’s extended PDUFA date of March 12, 2025. View the news 👇 https://t.co/Vb8ed0M5PB
-
-
Mashup Score: 6
Results from two phase 3 trials showed that topical tapinarof, once a day, was effective and safe in patients with atopic dermatitis as young as 2 years old.
Source: www.medscape.comCategories: General Medicine News, Allergy-ImmunologyTweet-
#Tapinarof Cream Effective For #Atopic #Dermatitis, Down to Age 2 Years https://t.co/ukQ0I4biU3
-
-
Mashup Score: 2FDA Accepts Dermavant’s sNDA for Tapinarof Cream 1% for Adults and Children With AD - 8 month(s) ago
The FDA’s PDUFA date is expected in quarter 4 of 2024.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
BREAKING TODAY: Dermavant Sciences announced that the US FDA has accepted its supplemental new drug application for #tapinarof cream 1% for the treatment of #atopicdermatitis in adults and children aged 2 years and older. https://t.co/GM3Twn3nsz
-
-
Mashup Score: 1Dermavant Shares Positive Safety and Efficacy Data From Analysis of ADORING Program for Atopic Dermatitis - 12 month(s) ago
The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
Dermavant Sciences announced recently additional positive safety and efficacy data from its phase 3 development program, ADORING, of #tapinarof cream, 1% in adults and children as young as 2 years of age with #AtopicDermatitis. https://t.co/k3eMggm9mm
-
Discussing FDA Approval of #Tapinarof Cream for #Atopic #Dermatitis, with John Browning, MD a pediatric dermatologist and an ADORING trial investigator, spoke with the HCPLive editorial team about the tapinarof approval and its significance. https://t.co/poZ7jB1TRO https://t.co/09qI6vs8Ix